A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Navitoclax (Primary) ; Gemcitabine
- Indications Breast cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 22 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 22 Dec 2011 Actual patients number (46) added as reported by ClinicalTrials.gov.
- 22 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.